EUCTR2020-001240-25-NL进行中（未招募）1 期
Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer - INSPIRE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Radboudumc
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Written informed consent.
- •2. Histological diagnosis of adenocarcinoma of the prostate. Patients who have no histological diagnosis must be willing to undergo a biopsy to prove prostate adenocarcinoma.
- •3. Metastatic Castration-Resistant Prostate Cancer (mCRPC), metastatic disease defined either by measurable disease by RECIST1.1 criteria and/or presence of bone-metastatic disease evaluable per PCWG3 criteria. For cohort 1, measurable disease is compulsory.
- •4. An immunogenic phenotype, consisting of one of the next criteria:
- •1, mismatch repair deficiency and/or a high mutational burden of >10 mutations per Mb (cluster A);
- •2, BRCA2 inactivation and/or BRCAness signature (cluster B);
- •3, a tandem duplication signature (cluster C).
- •5. Age =18 years.
- •6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 – 1.
- •7. PSA = 2 ng/ml.
- •8. Documented willingness to use an effective means of contraception while participating in the study and for 7 months post last dose of treatment (see section 4.5).
- •9. Documented ongoing castrate serum testosterone <50 ng/dL (<2.0 nM).
- •10. Received prior castration by orchiectomy and/or ongoing Luteinizing Hormone-Releasing Hormone (LH-RH) agonist treatment.
- •11. Progression of disease by PSA utilizing PCWG3 criteria and at least another of the following criteria;
- •a. Bone scan: disease progression as defined by at least 2 new lesions on bone scan.
- •b. Soft tissue disease progression defined by modified RECIST 1.1.
- •c. Clinical progression with worsening pain and the need for palliative radiotherapy for bone metastases.
- •12. Having a biopsiable metastatic lesion and willingness to undergo a baseline* and on-treatment tumour biopsy for next-generation sequencing and biomarker analyses. *When sufficient FFPE material is available from a biopsy in castrate-state, one may apply for a waiver for a new baseline biopsy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 26
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 49
排除标准
- •1. Prior treatment with checkpoint immunotherapy (CTLA-4, or PD-1 and PD-L1 antagonists) for cohort 1. For cohort 2 patients may have prior treatment with monotherapy CTLA-4 or PD-1 or PD-L1.
- •2. Surgery, chemotherapy within 4 weeks prior to trial entry / randomisation into the study. Any other therapies for prostate cancer, other than GnRH analogue therapy and osteoporosis preventing agents, are not allowed.
- •3. Radiotherapy within 2 weeks prior to trial entry. Radiation-related side effects higher than grade 1, or above baseline.
- •4. Participation in another interventional clinical trial and any concurrent treatment with any investigational drug within 4 weeks prior to trial entry / randomisation.
- •5. History of seizure or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumours, brain metastases, or alcoholism.
- •6. Untreated or symptomatic brain or leptomeningeal involvement.
- •7. Inadequate organ and bone marrow function as evidenced by: a. haemoglobin <6.2 mmol/L b. Absolute neutrophil count <1.0 x 109/L c. Platelet count < 75 x 109/L d. Albumin <30 g/dL. e. AST / SGOT and/or ALT / SGPT = 2.5 x ULN (= 5 x ULN if liver metastases present) f. Total bilirubin = 1.5 x ULN (except for patient with documented Gilbert’s disease) g. Serum Creatinine > 1.5 x ULN
- •8. Any of the following cardiac criteria; a. Any clinically significant abnormalities in rhythm, conduction, or morphology of a resting ECG (e.g., complete left bundle branch block, third degree heart block)
- •c. Experience of any of the following procedures or conditions in the preceding six months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, congestive heart failure NYHA = Grade2
- •d. Uncontrolled hypotension defined as – systolic blood pressure (BP) <90mmHg and/or diastolic BP <50mmHg
- •9. Clinically significant history of liver disease consistent with Child-Pugh Class B or C, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
- •10. History of clinically relevant auto-immune disease (including Crohn’s disease or ulcerative colitis). Any other finding giving reasonable suspicion of a disease or condition that contraindicates the use of nivolumab or ipilimumab or that may affect the interpretation of the results or renders the patients at high risk from treatment complications.
- •10. Need for chronic corticosteroid therapy of >10 mg of prednisolone or >0.5mg of dexamethasone per day or an equivalent dose of other anti-inflammatory corticosteroid, for the use of concomitant steroids on this trial please refer to section 12.1. Patients in which corticosteroids cannot be stopped prior to entering the trial are allowed a maximum of 10mg of prednisolone per day or equivalent. In the case of corticosteroid discontinuation, a 2-week (14 days) washout is required with a mandatory PSA check prior to starting the trial. If the PSA has declined compared to the value obtained prior to stopping corticosteroids, patients will not be eligible for study. Patients can only enter the study with a confirmed PSA increase.
- •11. Malignancies other than prostate cancer within 3 years prior to trial entry / randomization, except for adequately treated basal or squamous cell skin cancer and non-muscle invasive bladder cancer.
- •12. Active second malignancy, except basal or squamous cell skin cancer and non-muscle invasive bladder cancer. Other treated malignancies with curative
研究者
相似试验
已完成
2 期
Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate canceradvanced prostate cancermetastatic castration-resistant prostate cancer10038597NL-OMON49591Radboud Universitair Medisch Centrum69
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerEUCTR2016-001928-54-DKBristol-Myers Squibb International Corporation489
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code: 10036909Term: Prostate cancer metastatic Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2022-502909-15-00477
进行中（未招募）
1 期
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001928-54-DEBristol-Myers Squibb International Corporation489
进行中（未招募）
1 期
A Study to Evaluate Preliminary Efficacy of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate CancerEUCTR2016-001928-54-ESBristol-Myers Squibb International Corporation495